January 28, 2010

A Big Upgrade for SIGA Technologies

RBC Capital has picked SIGA to outperform citing their belief that they are on the verge of signing a large contract with the government to develop small-pox vaccine. The current target is $11, but could easily hit the $20 range depending on the size of the contract.

This article from the Fool in December noted that the company has a three year lead on any competitors product and that they appear to have the inside track on getting the product.

No comments: